Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Can J Cardiol. 2013 Oct;29(10):1158-64. doi: 10.1016/j.cjca.2013.04.033. Epub 2013 Jul 29.
Atrial fibrillation (AF) is a common arrhythmia associated with significant morbidity and mortality. There has been much debate about the relative merits of rate vs rhythm control strategies, and studies to date have failed to show advantage with a rhythm-control strategy using antiarrhythmic drugs (AADs). This is likely because of the inadequacies of our current AADs and the limitations of study designs. However, there is evidence that AADs improve symptoms and quality of life (QOL). Until trials are performed with more appropriate patient selection, and end points and better AADs and strategies for their use, rhythm control should not be abandoned and may continue to be beneficial in selected patients.
心房颤动（AF）是一种常见的心律失常，与显著的发病率和死亡率相关。关于速率控制策略与节律控制策略的相对优势一直存在很多争议，迄今为止的研究未能显示出抗心律失常药物（AAD）节律控制策略的优势。这可能是由于我们目前的 AAD 存在不足以及研究设计的局限性。然而，有证据表明 AAD 可改善症状和生活质量（QOL）。在使用更合适的患者选择、终点以及更好的 AAD 和使用策略进行试验之前，不应放弃节律控制，并且在选择的患者中可能仍然有益。
